\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space HPC AI ContinentThe purpose of the Large AI Grand Challenge is to foster the development of large-scale AI models in Europe and to substantially increase the visibility of Europe’s activity in this field.
The competition will reward innovative startups and SMEs for devising ambitious strategies and making commitments to develop large-scale AI models that will provide a competitive edge for Europe.
The expected outcome of the Large AI Grand Challenge is the selection of up to four proposals that will receive each up to 250 k€ in funding to create innovative foundational language models that will outperform state-of-the-art systems in a number of relevant tasks. The development of these models should necessarily involve the use of High-Performance Computing (HPC). The submission deadline is 16 January 2024.
To be eligible to apply to the Large AI Grand Challenge, applicants must meet the four following criteria:
Full information can be found on the call website.
Extra: there is an info session on 12 December.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
